$3.38
5.63% yesterday
Nasdaq, Nov 25, 10:04 pm CET
ISIN
US92859E1082
Symbol
VVOS

Vivos Therapeutics Inc Stock price

$3.38
+0.73 27.55% 1M
+1.28 60.95% 6M
-9.06 72.83% YTD
-0.85 20.06% 1Y
-65.37 95.08% 3Y
-221.37 98.50% 5Y
-221.37 98.50% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.18 5.63%
ISIN
US92859E1082
Symbol
VVOS
Sector
Industry

Key metrics

Market capitalization $16.34m
Enterprise Value $11.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.80
P/S ratio (TTM) P/S ratio 1.12
P/B ratio (TTM) P/B ratio 2.10
Revenue growth (TTM) Revenue growth 0.54%
Revenue (TTM) Revenue $14.58m
EBIT (operating result TTM) EBIT $-12.65m
Free Cash Flow (TTM) Free Cash Flow $-13.07m
Cash position $6.31m
EPS (TTM) EPS $-4.95
P/E forward negative
P/S forward 1.07
EV/Sales forward 0.77
Short interest 2.01%
Show more

Is Vivos Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Vivos Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Vivos Therapeutics Inc forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Vivos Therapeutics Inc forecast:

Buy
100%

Financial data from Vivos Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
15 15
1% 1%
100%
- Direct Costs 6.31 6.31
2% 2%
43%
8.27 8.27
2% 2%
57%
- Selling and Administrative Expenses 20 20
23% 23%
140%
- Research and Development Expense - -
-
-
-12 -12
35% 35%
-83%
- Depreciation and Amortization 0.59 0.59
8% 8%
4%
EBIT (Operating Income) EBIT -13 -13
34% 34%
-87%
Net Profit -13 -13
18% 18%
-86%

In millions USD.

Don't miss a Thing! We will send you all news about Vivos Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vivos Therapeutics Inc Stock News

Neutral
Seeking Alpha
11 days ago
Vivos Therapeutics, Inc. (NASDAQ:VVOS ) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Company Participants Kirk Huntsman - Chariman & CEO Brad Amman - CFO Conference Call Participants Scott Henry - Alliance Global Partners Lucas Ward - Ascendiant Capital Markets. Operator Good day, everyone, and welcome to the Vivos Therapeutics Third Quarter 2024 Earnings Conference Call.
Positive
Proactive Investors
12 days ago
Vivos Therapeutics (NASDAQ:VVOS), a medical technology targeting sleep issues such as obstructive sleep apnea (OSA) and snoring, had a strong third quarter marked by higher revenue and reduced operating expenses.  Revenue increased 17% year-over-year to $3.9 million compared to $3.3 million in the same period last year.
Neutral
GlobeNewsWire
13 days ago
LITTLETON, Colo., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company”) (NASDAQ: VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults), today announced it plan...
More Vivos Therapeutics Inc News

Company Profile

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). Its solutions are also offered for patients with mild-to-moderate obstructive sleep apnea (OSA). The company was founded by Gurdev Dave Singh, Susan McCullough, RaeAnn Byrnes, Todd Huntsman, and R. Kirk Huntsman on July 7, 2016 and is headquartered in Highlands Ranch, CO.

Head office United States
CEO R. Huntsman
Employees 114
Founded 2016
Website www.vivos.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today